Pfizer and its partner BioNTech have five potential COVID-19 vaccines in clinical trials, each of which is based on a different mRNA format. Now the companies are reporting that the most advanced candidate, BNT162b2, performed well in trials in which mice and macaques were infected with the coronavirus after inoculation. more